Phenotypes for Zbtb20 MGI:3639711 MGI Mouse

premature death ( J:87150 , J:121330 , J:141084 )

• high rate of premature (6 months or earlier) death (J:87150)

• mice show premature death of unclear etiology with >15% mortality exhibited by 6 months, compared to all other genotypes (J:121330)

increased susceptibility to pharmacologically induced seizures ( J:121330 )

• mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls

abnormal long-term object recognition memory ( J:121330 )

• at 4-7 months of age, mice transgenic mice with wild-type Mapt expression take longer to locate the platform in the cued version of the Morris water maze test compared to transgenic mice heterozygous or homozygous for Mapt deletion

abnormal spatial learning ( J:121330 , J:141084 )

• in the hidden platform version of the Morris water maze, non-trangenic controls, regardless of Mapt genotype learn the task over 3 days, whereas transgenic mice with wild-type expression of Mapt show no evidence of learning (J:121330)

• in probe trials where the platform is removed, mice show no learning, displaying no significantly elevated crossings of the target quadrant after 5 days of training (J:121330)

• in a Morris water maze, mice fail to favor the target platform location unlike wild-type mice (J:141084)

decreased anxiety-related response ( J:141084 )

• mice exhibit disinhibition-like behaviors in an elevated plus maze compared with wild-type mice

hyperactivity ( J:121330 , J:141084 )

• mice show hyperactivity in the Y-maze, a new cage, and elevated-plus maze compared to other transgenic mice or non-transgenic controls; this persists in mice 12-16 months of age (J:121330)

increased susceptibility to pharmacologically induced seizures ( J:121330 )

• mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls

amyloid beta deposits ( J:62290 , J:87150 , J:121330 )

• diffuse immunoreactive amyloid deposits detected in dentate gyrus and neocortex of mice aged 5 to 7 months old (J:62290)

• all mice exhibit plaques by age 8 to 10 months (J:62290)

• soluble and insoluble Abeta-40 and -42 peptide deposits at 6-10 months (J:87150)

• at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous null for Mapt (J:121330)

abnormal neuron morphology ( J:121330 )

• mice show neuritic dystrophy around amyloid plaques

abnormal neuron differentiation ( J:121330 )

• aberrant sprouting of hippocampal axons is observed in transgenic mice

neurodegeneration ( J:62290 )

• neurodegeneration is indicated by an age dependent decrease in density of synaptophysin-immunoreactive presynaptic terminals